Genomic and nongenomic effects of estrogen signaling in human endometrial cells: Involvement of the growth factor receptor signaling downstream AKT pathway

Reproductive Sciences

Volumn 14, Issue 7, 2007, Pages 646-654

  Gielen, Sussane C J P ^a   Santegoets, Lindy A M ^a   Kühne, Liesbeth C M ^b   Van Ijcken, Wilfred F J ^a   Boers Sijmons, Bianca ^a   Hanifi Moghaddam, Payman ^a   Helmerhorst, Theo J M ^a   Blok, Leen J ^a,c,d   Burger, Curt W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c Organon NV ^*  (Netherlands)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

AKT; Amphiregulin; Endothelial growth factor receptor; Estrogen; Insulin like growth factor receptor; Microarray; Tamoxifen

Indexed keywords

AMPHIREGULIN; ESTRADIOL; ESTROGEN; GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; SOMATOMEDIN C; TAMOXIFEN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CELL; ENZYME ACTIVATION; ENZYME INDUCTION; GENE CONTROL; GENOMICS; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; DNA MICROARRAY; DRUG EFFECT; ENDOMETRIUM; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MULTIGENE FAMILY; PHYSIOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; ENDOMETRIUM; ESTRADIOL; ESTROGENS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MULTIGENE FAMILY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN;

EID: 38449092445     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719107306872     Document Type: Article

References (33)

1. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998 ; 351: 1451-1467.
2. Bergman L., Beelen ML, Gallee MP, Hollema H., Benraadt J., van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet. 2000 ; 356: 881-887.
3. Buzdar AU, Hortobagyi GN Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol. 1998 ; 16: 348-353.
4. Nilsson S., Makela S., Treuter E., et al. Mechanisms of estrogen action. Physiol Rev. 2001 ; 81: 1535-1565.
5. O'Lone R., Frith MC, Karlsson EK, Hansen U. Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 2004 ; 18: 1859-1875.
6. Gottlicher M., Heck S., Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. J Mol Med. 1998 ; 76: 480-489.
7. Bramley T. Non-genomic progesterone receptors in the mammalian ovary: some unresolved issues. Reproduction. 2003 ; 125: 3-15.
8. Zhang Z., Kumar R., Santen RJ, Song RX The role of adapter protein Shc in estrogen non-genomic action. Steroids. 2004 ; 69: 523-529.
9. Filardo EJ, Thomas P. GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab. 2005 ; 16: 362-367.
10. Vivacqua A., Bonofiglio D., Recchia AG, et al. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol. 2006 ; 20: 631-646.
11. Giudice LC Growth factors and growth modulators in human uterine endometrium: their potential relevance to reproductive medicine. Fertil Steril. 1994 ; 61: 1-17.
12. Pfeiffer D., Spranger J., Al-Deiri M., et al. mRNA expression of ligands of the epidermal-growth-factor-receptor in the uterus. Int J Cancer. 1997 ; 72: 581-586.
13. Hwa V., Oh Y., Rosenfeld RG The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr Rev. 1999 ; 20: 761-787.
14. LeRoith D., Werner H., Neuenschwander S., Kalebic T., Helman LJ The role of the insulin-like growth factor-I receptor in cancer. Ann N Y Acad Sci. 1995 ; 766: 402-408.
15. Wells A. EGF receptor. Int J Biochem Cell Biol. 1999 ; 31: 637-643.
16. Surmacz E., Guvakova MA, Nolan MK, Nicosia RF, Sciacca L. Type I insulin-like growth factor receptor function in breast cancer. Breast Cancer Res Treat. 1998 ; 47: 255-267.
17. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001 ; 37 (suppl 4). S3 - S8.
18. Gielen SC, Hanekamp EE, Blok LJ, Huikeshoven FJ, Burger CW Steroid-modulated proliferation of human endometrial carcinoma cell lines: any role for insulin-like growth factor signaling? J Soc Gynecol Investig. 2005 ; 12: 58-64.
19. Karas M., Kleinman D., Danilenko M., et al. Components of the IGF system mediate the opposing effects of tamoxifen on endometrial and breast cancer cell growth. Prog Growth Factor Res. 1995 ; 6: 513-520.
20. Kleinman D., Karas M., Roberts CT, et al. Modulation of insulin-like growth factor I (IGF-I) receptors and membrane-associated IGF-binding proteins in endometrial cancer cells by estradiol. Endocrinology. 1995 ; 136: 2531-2537.
21. Gielen SC, Burger CW, Kuhne LC, Hanifi-Moghaddam P., Blok LJ Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J Soc Gynecol Investig. 2005 ; 12: e55 - e67.
22. Vendrell JA, Magnino F., Danis E., et al. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 ; 32: 397-414.
23. Hanifi-Moghaddam P., Sijmons B., Ott MC, et al. The hormone replacement therapy drug tibolone acts very similar to medroxyprogesterone acetate in an estrogen-and progesterone-responsive endometrial cancer cell line. J Mol Endocrinol. 2006 ; 37: 405-413.
24. Auffray C., Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem. 1980 ; 107: 303-314.
25. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004 ; 350: 1617-1628.
26. Bjornstrom L., Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol. 2005 ; 19: 833-842.
27. Gielen SC, Kuhne LC, Ewing PC, Blok LJ, Burger CW Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer. 2005 ; 12: 1037-1049.
28. Zhang H., Pan KH, Cohen SN Senescence-specific gene expression fingerprints reveal cell-type-dependent physical clustering of up-regulated chromosomal loci. Proc Natl Acad Sci U S A. 2003 ; 100: 3251-3256.
29. Migliaccio A., Di Domenico M., Castoria G., et al. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonism action. Cancer Res. 2005 ; 65: 10585-10593.
30. Migliaccio A., Castoria G., Di Domenico M., et al. Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci. 2006 ; 1089: 194-200.
31. Guzeloglu Kayisli O, Kayisli UA, Luleci G., Arici A. In vivo and in vitro regulation of AKT activation in human endometrial cells is estrogen dependent. Biol Reprod. 2004 ; 71: 714-721.
32. Lian Z., De Luca P., Di Cristofano A. Gene expression analysis reveals a signature of estrogen receptor activation upon loss of Pten in a mouse model of endometrial cancer. J Cell Physiol. 2006 ; 208: 255-266.
33. McCampbell AS, Broaddus RR, Loose DS, Davies PJ Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res. 2006 ; 12: 6373-6378.